Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997-2007

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 97, Issue 1, 2013, Pages 28-35

  Polen, Kara N D ^a   Rasmussen, Sonja A ^a   Riehle Colarusso, Tiffany ^a   Reefhuis, Jennita ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Antidepressants; Birth defects; Epidemiology; Pregnancy; Venlafaxine

Indexed keywords

VENLAFAXINE;

ADULT; ANENCEPHALUS; AORTA COARCTATION; ARTICLE; BIRTH DEFECT; CLEFT PALATE; CONTROLLED STUDY; EDUCATIONAL STATUS; ETHNICITY; FEMALE; FIRST TRIMESTER PREGNANCY; GASTROSCHISIS; HEART ATRIUM SEPTUM DEFECT; HUMAN; MATERNAL AGE; MOTHER; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RACE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANENCEPHALY; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AORTIC COARCTATION; CLEFT PALATE; CYCLOHEXANOLS; FEMALE; GASTROSCHISIS; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; MATERNAL EXPOSURE; ODDS RATIO; PREGNANCY; UNITED STATES;

EID: 84872387772     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23096     Document Type: Article

References (55)

1. Alwan S, Reefhuis J, Botto LD, et al. 2010. Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 203: 52.e1-52.e6.
2. Alwan S, Reefhuis J, Rasmussen SA, et al. 2011. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol 51: 264-270.
3. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356: 2684-2692.
4. Andrade SE, Raebel MA, Brown J, et al. 2008. Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198: 194.e1-194.e5.
5. Bar-Oz B, Einarson T, Einarson A, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 29: 918-926.
6. Bérard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80: 18-27.
7. Bonari L, Pinto N, Ahn E, et al. 2004. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49: 726-735.
8. Buznikov GA, Lambert HW, Lauder JM. 2001. Serotonin and serotonin-like substances as regulators of early embryogenesis and morphogenesis. Cell Tissue Res 305: 177-186.
9. Choi DS, Ward SJ, Messaddeq N, et al. 1997. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development 124: 1745-1755.
10. Cogswell ME, Bitsko RH, Anderka M, et al. 2009. Control selection and participation in an ongoing, population-based, case-control study of birth defects: the National Birth Defects Prevention Study. Am J Epidemiol 170: 975-985.
11. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16: 1075-1085.
12. Cooper WO, Willy ME, Pont SJ, Ray WA. 2007. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196: 544.e1-544.e5.
13. Correa A, Gilboa SM, Besser LM, et al. 2008. Diabetes mellitus and birth defects. Am J Obstet Gynecol 199: 237.e1-237.e9.
14. Côté F, Fligny C, Bayard E, et al. 2007. Maternal serotonin is crucial for murine embryonic development. Proc Natl Acad Sci U S A 104: 329-334.
15. da-Silva VA, Altenburg SP, Malheiros LR, et al. 1999. Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 32: 93-98.
16. Diav-Citrin O, Shechtman S, Weinbaum D, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Brit J Clin Pharmacol 66: 695-705.
17. Drews CD, Kraus JF, Greenland S. 1990. Recall bias in a case-control study of sudden infant death syndrome. Int J Epidemiol 19: 405-411.
18. Einarson A, Choi J, Einarson TR, Koren G. 2009. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 54: 242-246.
19. Einarson A, Fatoye B, Sarkar M, et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 158: 1728-1730.
20. Einarson A, Pistelli A, DeSantis M, et al. 2008. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165: 749-752.
21. Ferreira E, Carceller AM, Agogué C, et al. 2007. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 119: 52-59.
22. Grote NK, Bridge JA, Gavin AR, et al. 2010. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 67: 1012-1024.
23. Harman JS, Edlund MJ, Fortney JC. 2009. Trends in antidepressant utilization from 2001 to 2004. Psychiatr Serv 60: 611-616.
24. Hu YF, Caron MG, Sieber-Blum M. 2009. Norepinephrine transport-mediated gene expression in noradrenergic neurogenesis. BMC Genomics 10: 151.
25. Källén B. 2004a. Fluoxetine use in early pregnancy. Birth Defects Res B Dev Reprod Toxicol 71: 395-396.
26. Källén B. 2004b. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 158: 312-316.
27. Källén BA, Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79: 301-308.
28. Khoury MJ, James LM, Erickson JD. 1994. On the use of affected controls to address recall bias in case-control studies of birth-defects. Teratology 49: 273-281.
29. Lauder JM. 1988. Neurotransmitters as morphogens. Prog Brain Res 73: 365-387.
30. Lennestål R, Källén B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 27: 607-613.
31. Louik C, Lin AE, Werler MM, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356: 2675-2683.
32. Mackenzie SG, Lippman A. 1989. An investigation of report bias in a case-control study of pregnancy outcome. Am J Epidemiol 129: 65-75.
33. Marcus SC, Olfson M. 2010. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 67: 1265-1273.
34. Mitchell AA, Cottler LB, Shapiro S. 1986. Effect of questionnaire design on recall of drug exposure in pregnancy. Am J Epidemiol 123: 670-676.
35. Moiseiwitsch JR. 2000. The role of serotonin and neurotransmitters during craniofacial development. Crit Rev Oral Biol Med 11: 230-239.
36. Moiseiwitsch JR, Lauder JM. 1995. Serotonin regulates mouse cranial neural crest migration. Proc Natl Acad Sci U S A 92: 7182-7186.
37. Nebigil CG, Choi DS, Dierich A, et al. 2000. Serotonin 2B receptor is required for heart development. Proc Natl Acad Sci U S A 97: 9508-9513.
38. Nebigil CG, Maroteaux L. 2001. A novel role for serotonin in heart. Trends Cardiovasc Med 11: 329-335.
39. Oberlander TF, Warburton W, Misri S, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83: 68-76.
40. Olfson M, Marcus SC. 2009. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66: 848-856.
41. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67: 193-201.
42. Reis M, Källén B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40: 1723-1733.
43. Ren ZG, Pörzgen P, Zhang JM, et al. 2001. Autocrine regulation of norepinephrine transporter expression. Mol Cell Neurosci 17: 539-550.
44. Ren ZG, Pörzgen PP, Youn YH, Sieber-Blum M. 2003. Ubiquitous embryonic expression of the norepinephrine transporter. Dev Neurosci 25: 1-13.
45. Ross LE, McLean LM. 2006. Anxiety disorders during pregnancy and the postpartum period: a systematic review. J Clin Psychiatry 67: 1285-1298.
46. Schueler YB, Koesters M, Wieseler B, et al. 2011. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Acta Psychiatr Scand 123: 247-265.
47. Sieber-Blum M, Ren Z. 2000. Norepinephrine transporter expression and function in noradrenergic cell differentiation. Mol Cell Biochem 212: 61-70.
48. Sussman N. 2003. SNRIs versus SSRIs: mechanisms of action in treating depression and painful physical symptoms. Primary Care Companion J Clin Psychiatry 5(Suppl 7): 19-26.
49. Waller DK, Pujazon MA, Canfield MA, et al. 2000. Frequency of prenatal diagnosis of birth defects in Houston, Galveston and the Lower Rio Grande Valley, Texas 1995. Fetal Diagn Ther 15: 348-354.
50. Wichman CL, Moore KM, Lang TR, et al. 2009. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 84: 23-27.
51. Yaris F, Kadioglu M, Kesim M, et al. 2004. Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 19: 235-238.
52. Yonkers KA, Wisner KL, Stewart DE, et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31(3): 403-413.
53. Yoon PW, Rasmussen SA, Lynberg MC, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116 Suppl 1: 32-40.
54. Zhang JM, Dix J, Langtimm-Sedlak CJ, et al. 1997. Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine. J Neurobiol 32: 262-280.
55. Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med 313: 347-352.